Embryo Editing Gets Green Light in U.K.

Researchers at the Francis Crick Institute in London will use CRISPR/Cas9 to modify genes in early human embryos.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, NINASESResearchers in the U.K. will soon use precision genome-editing on human embryos in an effort to probe the mysteries of early development. And they’ll do it with the blessing of government regulators. On Monday (February 1), the U.K.’s Human Fertilisation and Embryology Authority (HFEA) made the unprecedented step of approving a project involving the editing of genes in early human embryos.

Scientists in China made headlines last year when they announced their application of CRISPR/Cas9 to modify structurally deficient human zygotes. The April Protein & Cell paper reporting the findings set off alarm bells across the life science community, dividing researchers between those who thought the move was premature and ill-advised and those who warned of the dangers of stifling such research.

The UK researchers who will apply the technique to early human embryos, which will be destroyed after seven days of growth, are the first scientists to conduct such experiments with clearance from their government’s regulatory authorities. “China has guidelines, but it is often unclear exactly what they are until you've done it and stepped over an unclear boundary,” Robin Lovell-Badge, scientific adviser to the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide